{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:53:14Z","timestamp":1784170394182,"version":"3.55.0"},"reference-count":208,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite their proven efficacy and huge contribution to the health of humankind, vaccines continue to be a source of concern for some individuals around the world. Vaccinations against COVID-19 increased the number of distressed people and intensified their distrust, particularly as the pandemic was still emerging and the populations were encouraged to be vaccinated under various slogans like \u201cback to normal life\u201d and \u201cstop coronavirus\u201d, goals which are still to be achieved. As fear of vaccination-related adverse events following immunization (AEFIs) is the main reason for vaccine hesitancy, we reviewed immune and autoimmune AEFIs in particular, though very rare, as the most worrisome aspect of the vaccines. Among others, autoimmune AEFIs of the most commonly administered COVID-19 vaccines include neurological ones such as Guillain-Barre syndrome, transverse myelitis, and Bell\u2019s palsy, as well as myocarditis. In addition, the newly introduced notion related to COVID-19 vaccines, \u201cvaccine-induced immune thrombotic thrombocytopenia\/vaccine-induced prothrombotic immune thrombotic thrombocytopenia\u201d (VITT\/VIPITT)\u201d, is of importance as well. Overviewing recent medical literature while focusing on the major immune and autoimmune AEFIs, demonstrating their rate of occurrence, presenting the cases reported, and their link to the specific type of COVID-19 vaccines represented the main aim of our work. In this narrative review, we illustrate the different vaccine types in current use, their associated immune and autoimmune AEFIs, with a focus on the 3 main COVID-19 vaccines (BNT162b2, mRNA-1273, and ChAdOx1). While the rate of AEFIs is extremely low, addressing the issue in this manner, in our opinion, is the best strategy for coping with vaccine hesitancy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.872683","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:25:54Z","timestamp":1656998754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Naim","family":"Mahroum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noy","family":"Lavine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviran","family":"Ohayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravend","family":"Seida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim","family":"Alwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Alrais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi","family":"Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"B1","unstructured":"WHO Director-General's Opening Remarks at the Media Briefing on COVID-192020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1093\/pubmed\/fdab122","article-title":"Correlates of COVID-19 Vaccine Hesitancy in Austria: Trust and the Government","volume":"44","author":"Schernhammer","year":"2022","journal-title":"J Public Health (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0262-4079(20)32025-X","article-title":"How to Stop Vaccine Hesitancy","volume":"248","author":"Vaughan","year":"2020","journal-title":"New Sci"},{"key":"B4","article-title":"A Future Vaccination Campaign Against COVID-19 at Risk of Vaccine Hesitancy and Politicisation","volume":"20","author":"Group","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5471.1593","article-title":"A Brief History of Polio Vaccines","volume":"288","author":"Blume","year":"2000","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1613577","article-title":"New Vaccines Against Epidemic Infectious Diseases","volume":"376","author":"Rottingen","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdaa230","article-title":"COVID-19 Vaccine Hesitancy Among Medical Students","volume":"43","author":"Lucia","year":"2021","journal-title":"J Public Health (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00012-8","article-title":"COVID-19 Vaccine Hesitancy in a Representative Working-Age Population in France: A Survey Experiment Based on Vaccine Characteristics","volume":"6","author":"Schwarzinger","year":"2021","journal-title":"Lancet Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2112543","article-title":"The Importance of Context in Covid-19 Vaccine Safety","volume":"385","author":"Lee","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13548506.2021.2014910","article-title":"COVID-19 Information Exposure and Vaccine Hesitancy: The Influence of Trust in Government and Vaccine Confidence","volume":"7","author":"Liu","year":"2021","journal-title":"Psychol Health Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400472111","article-title":"History of Vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2017-0176","article-title":"Principles of Vaccine Potency Assays","volume":"10","author":"Verch","year":"2018","journal-title":"Bioanalysis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.045","article-title":"Causal Relationship Between Immunological Responses and Adverse Reactions Following Vaccination","volume":"37","author":"Nakayama","year":"2019","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biologicals.2003.11.001","article-title":"Verification of Components of Acellular Pertussis Vaccines That Have Been Distributed Solely, Been in Routine Use for the Last Two Decades and Contributed Greatly to Control of Pertussis in Japan","volume":"32","author":"Kuno-Sakai","year":"2004","journal-title":"Biologicals"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0641-6","article-title":"Vaccine Chronicle in Japan","volume":"19","author":"Nakayama","year":"2013","journal-title":"J Infect Chemother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri2508","article-title":"B-Cell Responses to Vaccination at the Extremes of Age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/v12111324","article-title":"Application of Viral Vectors for Vaccine Development With a Special Emphasis on COVID-19","volume":"12","author":"Lundstrom","year":"2020","journal-title":"Viruses"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and Multipathogen Viral Vector Vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12883-021-02489-x","article-title":"Miller Fisher Syndrome Following BNT162b2 mRNA Coronavirus 2019 Vaccination","volume":"21","author":"Nishiguchi","year":"2021","journal-title":"BMC Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as Vaccine Vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 Vaccine Candidate Appears Safe and Effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/biology10080752","article-title":"Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines Among German Healthcare Workers","volume":"10","author":"Klugar","year":"2021","journal-title":"Biol (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct Gene Transfer Into Mouse Muscle In Vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA Vaccines - a New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-021-00432-6","article-title":"Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach","volume":"64","author":"Bhattacharya","year":"2022","journal-title":"Mol Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.012","article-title":"Herd Immunity: Understanding COVID-19","volume":"52","author":"Randolph","year":"2020","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00451-5","article-title":"COVID-19 Herd Immunity: Where Are We","volume":"20","author":"Fontanet","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"m1198","DOI":"10.1136\/bmj.m1198","article-title":"Covid-19: Risk Factors for Severe Disease and Death","volume":"368","author":"Jordan","year":"2020","journal-title":"BMJ"},{"key":"B33","unstructured":"FDA Approves First COVID-19 Vaccine2021"},{"key":"B34","unstructured":"Conditions of Authorisation for COVID-19 Vaccine Pfizer\/BioNTech (Regulation 174)2020"},{"key":"B35","unstructured":"Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine2020"},{"key":"B36","unstructured":"2020"},{"key":"B37","unstructured":"Regulatory Approval of Vaxzevria2020"},{"key":"B38","unstructured":"Coronavirus (COVID-19) Vaccinations2021"},{"key":"B39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.autrev.2016.09.022","article-title":"Guillain-Barre Syndrome","volume":"16","author":"Esposito","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre Syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre Syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre Syndrome: Pathogenesis, Diagnosis, Treatment and Prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4103\/0976-3147.118804","article-title":"Twelfth Cranial Nerve Involvement in Guillian Barre Syndrome","volume":"4","author":"Nanda","year":"2013","journal-title":"J Neurosci Rural Pract"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1128829","article-title":"Complications of Guillain-Barre Syndrome","volume":"12","author":"Wang","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jcrc.2018.01.016","article-title":"Characteristics, Incidence and Outcome of Patients Admitted to Intensive Care Unit With Guillain-Barre Syndrome in Australia and New Zealand","volume":"45","author":"Ancona","year":"2018","journal-title":"J Crit Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693005","article-title":"Guillain-Barre Syndrome","volume":"39","author":"Malek","year":"2019","journal-title":"Semin Neurol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barre Syndrome After Measles-Mumps-Rubella Vaccination","volume":"138","author":"Patja","year":"2001","journal-title":"J Pediatr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.119","article-title":"Vaccine-Preventable Diseases, Vaccines and Guillain-Barre' Syndrome","volume":"37","author":"Principi","year":"2019","journal-title":"Vaccine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.7759\/cureus.13426","article-title":"Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05733-x","article-title":"Guillain-Barre Syndrome Following the First Dose of Pfizer-BioNTech COVID-19 Vaccine: Case Report and Review of Reported Cases","volume":"43","author":"Bouattour","year":"2021","journal-title":"Neurol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102540","DOI":"10.1016\/j.amsu.2021.102540","article-title":"Post-COVID-19 Vaccine Guillain-Barre Syndrome; First Reported Case From Qatar","volume":"67","author":"Razok","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of Recurrent Guillain-Barre Syndrome After mRNA COVID-19 Vaccine Bnt162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.018","article-title":"Real-World Safety Data for the Pfizer BNT162b2 SARS-CoV-2 Vaccine: Historical Cohort Study","volume":"28","author":"Shasha","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B54","doi-asserted-by":"publisher","first-page":"108818","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barre Syndrome Is Infrequent Among Recipients of the BNT162b2 mRNA COVID-19 Vaccine","volume":"230","author":"Garcia-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18291","article-title":"Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine","volume":"13","author":"Dalwadi","year":"2021","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13760-021-01838-4","article-title":"Guillain-Barre Syndrome Following COVID-19 Vaccine mRNA-1273: A Case Report","volume":"12","author":"Masuccio","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27461","article-title":"Acute-Onset Polyradiculoneuropathy After SARS-CoV2 Vaccine in the West and North Midlands, United Kingdom","volume":"65","author":"Loo","year":"2022","journal-title":"Muscle Nerve"},{"key":"B58","unstructured":"Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC)2021"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barre Syndrome Variant Occurring After SARS-CoV-2 Vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327027","article-title":"Bilateral Facial Weakness With Paraesthesia Variant of Guillain-Barre Syndrome Following Vaxzevria COVID-19 Vaccine","volume":"93","author":"Bonifacio","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243629","article-title":"Case of Guillain-Barre Syndrome Following COVID-19 Vaccine","volume":"14","author":"Hasan","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"106887","DOI":"10.1016\/j.clineuro.2021.106887","article-title":"Guillain-Barre Syndrome After AstraZeneca COVID-19-Vaccination: A Causal or Casual Association","volume":"208","author":"Introna","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244527","article-title":"Guillain-Barre Syndrome Presenting With Facial Diplegia Following COVID-19 Vaccination in Two Patients","volume":"14","author":"Kanabar","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barre Syndrome Following ChAdOx1-S\/nCoV-19 Vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244125","article-title":"Guillain-Barre Syndrome After COVID-19 Vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"577691","DOI":"10.1016\/j.jneuroim.2021.577691","article-title":"Sensory Guillain-Barre Syndrome Following the ChAdOx1 Ncov-19 Vaccine: Report of Two Cases and Review of Literature","volume":"359","author":"Min","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"577719","DOI":"10.1016\/j.jneuroim.2021.577719","article-title":"AstraZeneca COVID-19 Vaccine and Guillain- Barre Syndrome in Tasmania: A Causal Link","volume":"360","author":"Oo","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and Cohort Study Finds No Association Between COVID-19 and Guillain-Barre Syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barre Syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"B70","unstructured":"Guidance: Information for Healthcare Professionals on Guillain-Barr\u00e9 Syndrome (GBS) Following COVID-19 Vaccination2021"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.16496","article-title":"Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barre Syndrome, February-July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ncl.2012.09.008","article-title":"Transverse Myelitis","volume":"31","author":"Beh","year":"2013","journal-title":"Neurol Clin"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-006-0011-1","article-title":"Demyelinating Disorders: Update on Transverse Myelitis","volume":"6","author":"Krishnan","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309345730","article-title":"Transverse Myelitis and Vaccines: A Multi-Analysis","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8747-21","article-title":"A Case of Refractory Longitudinally Extensive Transverse Myelitis After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in a Japanese Man","volume":"61","author":"Miyaue","year":"2021","journal-title":"Intern Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","article-title":"Neurologic Adverse Events Among 704,003 First-Dose Recipients of the BNT162b2 mRNA COVID-19 Vaccine in Mexico: A Nationwide Descriptive Study","volume":"229","author":"Garcia-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51447","article-title":"Acute Disseminated Encephalomyelitis in a Patient Vaccinated Against SARS-CoV-2","volume":"8","author":"Kania","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e17961","DOI":"10.7759\/cureus.17961","article-title":"Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine","volume":"13","author":"Fujikawa","year":"2021","journal-title":"Cureus"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/vaccines9091008","article-title":"Acute Transverse Myelitis Following COVID-19 Vaccination","volume":"9","author":"Gao","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A Systematic Review of Cases of CNS Demyelination Following COVID-19 Vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J Neuroimmunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 Vaccine Efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.05.018","article-title":"Transverse Myelitis","volume":"11","author":"Borchers","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/medicina57101010","article-title":"Acute Transverse Myelitis After COVID-19 Vaccination","volume":"57","author":"Hsiao","year":"2021","journal-title":"Med (Kaunas)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab069","article-title":"COVID-19 Vaccination-Associated Myelitis","volume":"114","author":"Malhotra","year":"2021","journal-title":"QJM"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0470","article-title":"Lessons of the Month 1: Longitudinal Extensive Transverse Myelitis Following AstraZeneca COVID-19 Vaccination","volume":"21","author":"Notghi","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"577606","DOI":"10.1016\/j.jneuroim.2021.577606","article-title":"A Case of Longitudinally Extensive Transverse Myelitis Following Vaccination Against Covid-19","volume":"358","author":"Pagenkopf","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12883-021-02427-x","article-title":"Longitudinal Extensive Transverse Myelitis Following ChAdOx1 nCOV-19 Vaccine: A Case Report","volume":"21","author":"Tan","year":"2021","journal-title":"BMC Neurol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653786","article-title":"Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 Ncov-19 Vaccine (Azd1222)","volume":"12","author":"Roman","year":"2021","journal-title":"Front Immunol"},{"key":"B90","first-page":"1204","article-title":"Bell's Palsy","volume":"2014","author":"Holland","year":"2014","journal-title":"BMJ Clin Evid"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09282-4","article-title":"The Etiology of Bell's Palsy: A Review","volume":"267","author":"Zhang","year":"2020","journal-title":"J Neurol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000447","article-title":"Bell's Palsy","volume":"23","author":"Reich","year":"2017","journal-title":"Continuum (Minneap Minn)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"N Engl J Med"},{"key":"B94","unstructured":"Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA2020"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00076-1","article-title":"Bell's Palsy and SARS-CoV-2 Vaccines","volume":"21","author":"Ozonoff","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10462-4","article-title":"Bell's Palsy Following COVID-19 Vaccination","volume":"268","author":"Colella","year":"2021","journal-title":"J Neurol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.lanepe.2021.100236","article-title":"Association Between Vaccination With the BNT162b2 mRNA COVID-19 Vaccine and Bell's Palsy: A Population-Based Study","volume":"11","author":"Shibli","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinimag.2021.10.010","article-title":"Left Bell's Palsy Following the First Dose of mRNA-1273 SARS-CoV-2 Vaccine: A Case Report","volume":"82","author":"Cellina","year":"2022","journal-title":"Clin Imaging"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15935","article-title":"Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine","volume":"13","author":"Iftikhar","year":"2021","journal-title":"Cureus"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10617-3","article-title":"Bell's Palsy Following a Single Dose of mRNA SARS-CoV-2 Vaccine: A Case Report","volume":"269","author":"Martin-Villares","year":"2022","journal-title":"J Neurol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.08.071","article-title":"Facial Nerve Palsy Following the Administration of COVID-19 mRNA Vaccines: Analysis of a Self-Reporting Database","volume":"111","author":"Sato","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"120030","DOI":"10.1016\/j.jns.2021.120030","article-title":"Hospital-Based Observational Study of Neurological Disorders in Patients Recently Vaccinated With COVID-19 mRNA Vaccines","volume":"430","author":"Koh","year":"2021","journal-title":"J Neurol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.2219","article-title":"Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database","volume":"181","author":"Renoud","year":"2021","journal-title":"JAMA Intern Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309563","article-title":"Bell's Palsy: Aetiology, Clinical Features and Multidisciplinary Care","volume":"86","author":"Eviston","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological Complications After First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26182","article-title":"Postvaccinal Encephalitis After ChAdOx1 Ncov-19","volume":"90","author":"Zuhorn","year":"2021","journal-title":"Ann Neurol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12879-022-07186-9","article-title":"Herpes Simplex Encephalitis Following ChAdOx1 Ncov-19 Vaccination: A Case Report and Review of the Literature","volume":"22","author":"Moslemi","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.02.009","article-title":"A Case of Encephalitis Following COVID-19 Vaccine","volume":"28","author":"Kobayashi","year":"2022","journal-title":"J Infect Chemother"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243173","article-title":"Acute Encephalitis, Myoclonus and Sweet Syndrome After mRNA-1273 Vaccine","volume":"14","author":"Torrealba-Acosta","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Myocarditis: A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur Heart J"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800028","article-title":"Myocarditis","volume":"360","author":"Cooper","year":"2009","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60648-X","article-title":"Myocarditis","volume":"379","author":"Sagar","year":"2012","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306363","article-title":"Clinical Presentation and Diagnosis of Myocarditis","volume":"101","author":"Caforio","year":"2015","journal-title":"Heart"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying Causes and Long-Term Survival in Patients With Initially Unexplained Cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.09.054","article-title":"Myocarditis and Pericarditis After Immunization: Gaining Insights Through the Vaccine Adverse Event Reporting System","volume":"273","author":"Mei","year":"2018","journal-title":"Int J Cardiol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118283","article-title":"A Prospective Study of the Incidence of Myocarditis\/Pericarditis and New Onset Cardiac Symptoms Following Smallpox and Influenza Vaccination","volume":"10","author":"Engler","year":"2015","journal-title":"PLoS One"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis Following Smallpox Vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.4266\/acc.2017.00045","article-title":"Acute Fulminant Myocarditis Following Influenza Vaccination Requiring Extracorporeal Membrane Oxygenation","volume":"34","author":"Kim","year":"2019","journal-title":"Acute Crit Care"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.05.005","article-title":"Hemodynamic Collapse After Influenza Vaccination: A Vaccine-Induced Fulminant Myocarditis","volume":"36","author":"Nagano","year":"2020","journal-title":"Can J Cardiol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.023","article-title":"Serious Adverse Events Rarely Reported After Trivalent Inactivated Influenza Vaccine (TIV) in Children 6-23 Months of Age","volume":"27","author":"Rosenberg","year":"2009","journal-title":"Vaccine"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10087-9","article-title":"COVID-19 and Myocarditis: A Systematic Review and Overview of Current Challenges","volume":"27","author":"Castiello","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis Following COVID-19 mRNA Vaccination","volume":"39","author":"Abu Mouch","year":"2021","journal-title":"Vaccine"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055913","article-title":"Myocarditis After BNT162b2 and mRNA-1273 Vaccination","volume":"144","author":"Larson","year":"2021","journal-title":"Circulation"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15576","article-title":"Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines","volume":"13","author":"Vidula","year":"2021","journal-title":"Cureus"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military","volume":"6","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis After Covid-19 Vaccination in a Large Health Care Organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis After BNT162b2 mRNA Vaccine Against Covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.3471","article-title":"Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children","volume":"6","author":"Dionne","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update From the Advisory Committee on Immunization Practices - United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B133","unstructured":"Coronavirus Vaccine - Weekly Summary of Yellow Card Reporting2021"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13443","article-title":"Myocarditis and Pericarditis After Vaccination for COVID-19","volume":"326","author":"Diaz","year":"2021","journal-title":"JAMA"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis With COVID-19 mRNA Vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab278","article-title":"A Case of Myopericarditis With Pleuritis Following AstraZeneca Covid-19 Vaccination","volume":"114","author":"Hung","year":"2022","journal-title":"QJM"},{"key":"B137","unstructured":"COVID-19 Vaccines: Update on Ongoing Evaluation of Myocarditis and Pericarditis2021"},{"key":"B138","unstructured":"Guidance: Myocarditis and Pericarditis After COVID-19 Vaccination: Clinical Management Guidance for Healthcare Professionals2021"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012938","article-title":"Anti-Platelet Factor 4 Antibodies Causing VITT do Not Cross-React With SARS-CoV-2 Spike Protein","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 After ChAdOx1 Ncov-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"B142","unstructured":"COVID-19 Vaccine AstraZeneca: PRAC Investigating Cases of Thromboembolic Events - Vaccine\u2019s Benefits Currently Still Outweigh Risks2021"},{"key":"B143","unstructured":"WHO Backs AstraZeneca COVID Vaccine Amid Clotting Concerns; Green Lights Johnson & Johnson Shots2021"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01608-1","article-title":"Cerebral Venous Thrombosis After Vaccination Against COVID-19 in the UK: A Multicentre Cohort Study","volume":"398","author":"Perry","year":"2021","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination With Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population Based Cohort Study","volume":"373","author":"Pottegard","year":"2021","journal-title":"BMJ"},{"key":"B146","unstructured":"Astrazeneca\u2019s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots With Low Blood Platelets2021"},{"key":"B147","doi-asserted-by":"publisher","first-page":"oeab014","DOI":"10.1093\/ehjopen\/oeab014","article-title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia: Current Evidence, Potential Mechanisms, Clinical Implications, and Future Directions","volume":"1","author":"Marchandot B","year":"2021","journal-title":"Eur Heart J Open"},{"key":"B148","doi-asserted-by":"publisher","first-page":"102663","DOI":"10.1016\/j.jaut.2021.102663","article-title":"Perspectives on Vaccine Induced Thrombotic Thrombocytopenia","volume":"121","author":"Dotan","year":"2021","journal-title":"J Autoimmun"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779453","article-title":"Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis","volume":"12","author":"Ostrowski","year":"2021","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody Epitopes in Vaccine-Induced Immune Thrombotic Thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 Ncov-19) Covid-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 Ncov-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01245","article-title":"Immune Thrombocytopenia Associated With Pfizer-BioNTech's BNT162b2 mRNA COVID-19 Vaccine","volume":"25","author":"Akiyama","year":"2021","journal-title":"IDCases"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15418","article-title":"First Report of a De Novo iTTP Episode Associated With an mRNA-Based Anti-COVID-19 Vaccination","volume":"19","author":"de Bruijn","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B155","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105906","article-title":"Cerebral Venous Thrombosis After BNT162b2 mRNA SARS-CoV-2 Vaccine","volume":"30","author":"Dias","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B156","first-page":"341","article-title":"Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine","volume":"23","author":"Ganzel","year":"2021","journal-title":"Isr Med Assoc J"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.931478","article-title":"A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination","volume":"22","author":"King","year":"2021","journal-title":"Am J Case Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15420","article-title":"Acquired Thrombotic Thrombocytopenic Purpura: A Rare Disease Associated With BNT162b2 Vaccine","volume":"19","author":"Maayan","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B159","article-title":"[Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination]","volume":"62","author":"Matsumura","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2021.10.002","article-title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia After the BNT162b2 mRNA Covid-19 Vaccine: A Case Study","volume":"208","author":"Rodriguez","year":"2021","journal-title":"Thromb Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03190-y","article-title":"Thrombotic Thrombocytopenic Purpura: A New Menace After COVID Bnt162b2 Vaccine","volume":"114","author":"Waqar","year":"2021","journal-title":"Int J Hematol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2169\/internalmedicine.8568-21","article-title":"Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient","volume":"61","author":"Yoshida","year":"2021","journal-title":"Intern Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","article-title":"Risk of Thrombocytopenia and Thromboembolism After Covid-19 Vaccination and SARS-CoV-2 Positive Testing: Self-Controlled Case Series Study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01408-4","article-title":"First-Dose ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic and Hemorrhagic Events in Scotland","volume":"27","author":"Simpson","year":"2021","journal-title":"Nat Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242678","article-title":"Immune Thrombocytopenic Purpura and Acute Liver Injury After COVID-19 Vaccine","volume":"14","author":"Hines","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B166","doi-asserted-by":"publisher","first-page":"4130138","DOI":"10.1155\/2021\/4130138","article-title":"Recurrence of Thrombotic Thrombocytopenic Purpura After mRNA-1273 COVID-19 Vaccine Administered Shortly After COVID-19","volume":"2021","author":"Karabulut","year":"2021","journal-title":"Case Rep Hematol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14099","article-title":"Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine","volume":"13","author":"Malayala","year":"2021","journal-title":"Cureus"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.772424","article-title":"Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA-1273","volume":"8","author":"Su","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26128","article-title":"Familial Thrombocytopenia Flare-Up Following the First Dose of mRNA-1273 Covid-19 Vaccine","volume":"96","author":"Toom","year":"2021","journal-title":"Am J Hematol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.054","article-title":"Thrombocytopenia Including Immune Thrombocytopenia After Receipt of mRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"39","author":"Welsh","year":"2021","journal-title":"Vaccine"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia Following Pfizer and Moderna SARS-CoV-2 Vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am J Hematol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"2100956","DOI":"10.1183\/13993003.00956-2021","article-title":"Vaccination Against COVID-19: Insight From Arterial and Venous Thrombosis Occurrence Using Data From VigiBase","volume":"58","author":"Smadja","year":"2021","journal-title":"Eur Respir J"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26172","article-title":"COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany","volume":"90","author":"Schulz","year":"2021","journal-title":"Ann Neurol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15029","article-title":"Post-SARS-CoV-2-Vaccination Cerebral Venous Sinus Thrombosis: An Analysis of Cases Notified to the European Medicines Agency","volume":"28","author":"Krzywicka","year":"2021","journal-title":"Eur J Neurol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"n1005","DOI":"10.1136\/bmj.n1005","article-title":"Covid-19: Risk of Cerebral Blood Clots From Disease is 10 Times That From Vaccination, Study Finds","volume":"373","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12813","article-title":"Severe Bleeding Events in Adults and Children With Primary Immune Thrombocytopenia: A Systematic Review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.04.014","article-title":"Vaccinations and Secondary Immune Thrombocytopenia With Antiphospholipid Antibodies by Human Papillomavirus Vaccine","author":"Bizjak","year":"2016","journal-title":"Semin Hematol"},{"key":"B180","article-title":"Immune Thrombocytopenic Purpura (ITP) Triggered by COVID-19 Infection and Vaccination","volume":"23","author":"David","year":"2021","journal-title":"Isr Med Assoc J"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05000516","article-title":"Minimal Change Disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2369-10-21","article-title":"Minimal Change Nephrotic Syndrome in an 82 Year Old Patient Following a Tetanus-Diphteria-Poliomyelitis-Vaccination","volume":"10","author":"Clajus","year":"2009","journal-title":"BMC Nephrol"},{"key":"B183","article-title":"Minimal Change Nephrotic Syndrome in a 65-Year-Old Patient Following Influenza Vaccination","volume":"54","author":"Kielstein","year":"2000","journal-title":"Clin Nephrol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5414\/CNP58068","article-title":"Minimal Change Nephrotic Syndrome, Lymphadenopathy and Hyperimmunoglobulinemia After Immunization With a Pneumococcal Vaccine","volume":"58","author":"Kikuchi","year":"2002","journal-title":"Clin Nephrol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.03.010","article-title":"Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine","volume":"78","author":"Lebedev","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.035","article-title":"Minimal Change Disease and Acute Kidney Injury Following the Pfizer-BioNTech COVID-19 Vaccine","volume":"100","author":"D'Agati","year":"2021","journal-title":"Kidney Int"},{"key":"B187","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1053\/j.ajkd.2021.05.003","article-title":"An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine","volume":"78","author":"Maas","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.006","article-title":"Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine","volume":"78","author":"Komaba","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B189","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12882-021-02583-9","article-title":"Minimal Change Disease Following the Moderna COVID-19 Vaccine: First Case Report","volume":"22","author":"Thappy","year":"2021","journal-title":"BMC Nephrol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.011","article-title":"Histologic Correlates of Gross Hematuria Following Moderna COVID-19 Vaccine in Patients With IgA Nephropathy","volume":"100","author":"Kudose","year":"2021","journal-title":"Kidney Int"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.kint.2021.03.002","article-title":"Gross Hematuria Following Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2 in 2 Patients With IgA Nephropathy","volume":"99","author":"Negrea","year":"2021","journal-title":"Kidney Int"},{"key":"B192","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.ekir.2021.06.024","article-title":"Nephrotic Syndrome Following ChAdOx1 Ncov-19 Vaccine Against SARScoV-2","volume":"6","author":"Anupama","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab153","article-title":"Adult-Onset Nephrotic Syndrome Following Coronavirus Disease Vaccination","volume":"15","author":"Biradar","year":"2022","journal-title":"Clin Kidney J"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.06.008","article-title":"Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report","volume":"78","author":"Leclerc","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1326","article-title":"Rapid Whole-Blood Assay to Detect SARS-CoV-2-Specific Memory T-Cell Immunity Following a Single Dose of AstraZeneca ChAdOx1-S COVID-19 Vaccine","volume":"10","author":"Lineburg","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.017","article-title":"ANCA Glomerulonephritis After the Moderna COVID-19 Vaccination","volume":"100","author":"Sekar","year":"2021","journal-title":"Kidney Int"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.016","article-title":"De Novo Vasculitis After mRNA-1273 (Moderna) Vaccination","volume":"100","author":"Anderegg","year":"2021","journal-title":"Kidney Int"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.765447","article-title":"Case Report: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B199","doi-asserted-by":"publisher","first-page":"102745","DOI":"10.1016\/j.jaut.2021.102745","article-title":"Autoimmune Hepatitis After SARS-CoV-2 Vaccine: New-Onset or Flare-Up","volume":"125","author":"Avci","year":"2021","journal-title":"J Autoimmun"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.014","article-title":"Autoimmune Hepatitis Developing After the ChAdOx1 Ncov-19 (Oxford-AstraZeneca) Vaccine","volume":"75","author":"Clayton-Chubb","year":"2021","journal-title":"J Hepatol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"102688","DOI":"10.1016\/j.jaut.2021.102688","article-title":"Auto-Immune Hepatitis Following COVID Vaccination","volume":"123","author":"Rela","year":"2021","journal-title":"J Autoimmun"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.031","article-title":"Immune-Mediated Hepatitis With the Moderna Vaccine, No Longer a Coincidence But Confirmed","volume":"76","author":"Zin Tun","year":"2021","journal-title":"J Hepatol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B204","doi-asserted-by":"publisher","first-page":"107970","DOI":"10.1016\/j.intimp.2021.107970","article-title":"Autoimmune Phenomena Following SARS-CoV-2 Vaccination","volume":"99","author":"Ishay","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05523-5","article-title":"Guillain-Barre Syndrome Following BNT162b2 COVID-19 Vaccine","volume":"42","author":"Trimboli","year":"2021","journal-title":"Neurol Sci"},{"key":"B206","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00415-021-10647-x","article-title":"Acute Bilateral Optic\/Chiasm Neuritis With Longitudinal Extensive Transverse Myelitis in Longstanding Stable Multiple Sclerosis Following Vector-Based Vaccination Against the SARS-CoV-2","volume":"269","author":"Helmchen","year":"2022","journal-title":"J Neurol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15147","article-title":"Neurological Autoimmune Diseases Following Vaccinations Against SARS-CoV-2: A Case Series","volume":"29","author":"Kaulen","year":"2022","journal-title":"Eur J Neurol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.kint.2021.06.005","article-title":"Relapse of Minimal Change Disease Following the AstraZeneca COVID-19 Vaccine","volume":"100","author":"Morlidge","year":"2021","journal-title":"Kidney Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.872683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T05:26:05Z","timestamp":1656998765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.872683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":208,"alternative-id":["10.3389\/fimmu.2022.872683"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.872683","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"article-number":"872683"}}